JS6
Based on 1 publication(s) in Google Scholar
JS6 is a Bcl3 inhibitor. JS6 attenuates the binding of Bcl3 to NF-κB1 (p50), disrupts the binding of Bcl3 to NF-κB family proteins p50 and p52, and inhibits the NF-κB signaling pathway. JS6 is applicable to breast cancer-related research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.49%
- CAS No.: 950244-33-4
- 화학식: C20H22FN3O3
- 분자량:371.41
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) JS6
More
Biological Activity
제품 설명
|
Bcl3 |
p50 |
p52 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF-10A | IC50 |
7.4 μM
|
Reduction of cell viability in non-tumorigenic breast MCF-10A cells measured after 24 hours by Cell Titre Blue assay.
Reduction of cell viability in non-tumorigenic breast MCF-10A cells measured after 24 hours by Cell Titre Blue assay.
|
WO2015014972A1 |
| MDA-MB-231 | IC50 |
5.2 μM
|
Reduction of cell viability in triple-negative breast cancer MDA-MB-231 cells measured after 24 hours by Cell Titre Blue assay.
Reduction of cell viability in triple-negative breast cancer MDA-MB-231 cells measured after 24 hours by Cell Titre Blue assay.
|
WO2015014972A1 |
| SK-BR-3 | IC50 |
4.7 μM
|
Reduction of cell viability in HER2-positive breast cancer SKBR3 cells measured after 24 hours by Cell Titre Blue assay.
Reduction of cell viability in HER2-positive breast cancer SKBR3 cells measured after 24 hours by Cell Titre Blue assay.
|
WO2015014972A1 |
| HEK293 | IC50 |
4.2 μM
|
Inhibition of Bcl-3 binding to NFKB1 (p50) in HEK-293 cells overexpressing FLAG-tagged Bcl-3 measured after 24 hours by indirect sandwich ELISA assay.
Inhibition of Bcl-3 binding to NFKB1 (p50) in HEK-293 cells overexpressing FLAG-tagged Bcl-3 measured after 24 hours by indirect sandwich ELISA assay.
|
WO2015014972A1 |
| MDA-MB-231 | IC50 |
2.7 μM
|
Inhibition of NF-κB signalling in MDA-MB-231 cells overexpressing Bcl-3 measured after 24 hours pre-incubation followed by 48 hours post-transfection incubation using NF-κB promoter-reporter (luciferase) assay.
Inhibition of NF-κB signalling in MDA-MB-231 cells overexpressing Bcl-3 measured after 24 hours pre-incubation followed by 48 hours post-transfection incubation using NF-κB promoter-reporter (luciferase) assay.
|
WO2015014972A1 |
| HEK293 | IC50 |
5.9 μM
|
Inhibition of NF-κB signalling in HEK-293 cells overexpressing Bcl-3 measured after 24 hours pre-incubation followed by 48 hours post-transfection incubation using NF-κB promoter-reporter (luciferase) assay.
Inhibition of NF-κB signalling in HEK-293 cells overexpressing Bcl-3 measured after 24 hours pre-incubation followed by 48 hours post-transfection incubation using NF-κB promoter-reporter (luciferase) assay.
|
WO2015014972A1 |
| HEK293 | IC50 |
5.7 μM
|
Inhibition of NF-κB signalling in HEK-293 cells overexpressing Bcl-3 and p52 measured after 24 hours pre-incubation followed by 48 hours post-transfection incubation using NF-κB promoter-reporter (luciferase) assay.
Inhibition of NF-κB signalling in HEK-293 cells overexpressing Bcl-3 and p52 measured after 24 hours pre-incubation followed by 48 hours post-transfection incubation using NF-κB promoter-reporter (luciferase) assay.
|
WO2015014972A1 |
| MDA-MB-231 | IC50 |
4.8 μM
|
Reduction of cell motility in MDA-MB-231 cells overexpressing Bcl-3 measured after 24 hours pre-incubation followed by 24 hours Boyden Chamber incubation.
Reduction of cell motility in MDA-MB-231 cells overexpressing Bcl-3 measured after 24 hours pre-incubation followed by 24 hours Boyden Chamber incubation.
|
WO2015014972A1 |
In Vitro
JS6 potently inhibits Bcl3 activity in cancer cells, reducing Bcl3-NF-κB1 binding, tumor colony formation, and cancer cell migration[1].
JS6 (Compound 1a) (24 h) reduces the viability of MCF-10A, MDA-MB-231 and SKBR3 breast cancer cells[2].
JS6 (24 h pre-incubation followed by 24 h chamber incubation) reduces the motility of MDA-MB-231 cells overexpressing Bcl-3[2].
JS6 (24 h) inhibits the binding of Bcl-3 to p50 in HEK-293 cells overexpressing FLAG-tagged Bcl-3[2].
JS6 (pre-incubated for 24 h, followed by 48 h of incubation after transfection) inhibits the NF-κB signaling pathway in Bcl-3-overexpressing MDA-MB-231 cells, Bcl-3-overexpressing HEK-293 cells, and HEK-293 cells overexpressing both Bcl-3 and p52[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 950244-33-4
-
Appearance Solid
-
분자량 371.41
-
화학식 C20H22FN3O3
-
Color White to off-white
-
SMILES
O=C(NCCN1CCOCC1)C2=CC=CC=C2NC(C3=CC=CC=C3F)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
용액&용해도
In Vitro:
DMSO : 50 mg/mL (134.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
순도&문서
-
Data Sheet (283 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6924 mL | 13.4622 mL | 26.9244 mL | 67.3111 mL |
| 5 mM | 0.5385 mL | 2.6924 mL | 5.3849 mL | 13.4622 mL | |
| 10 mM | 0.2692 mL | 1.3462 mL | 2.6924 mL | 6.7311 mL | |
| 15 mM | 0.1795 mL | 0.8975 mL | 1.7950 mL | 4.4874 mL | |
| 20 mM | 0.1346 mL | 0.6731 mL | 1.3462 mL | 3.3656 mL | |
| 25 mM | 0.1077 mL | 0.5385 mL | 1.0770 mL | 2.6924 mL | |
| 30 mM | 0.0897 mL | 0.4487 mL | 0.8975 mL | 2.2437 mL | |
| 40 mM | 0.0673 mL | 0.3366 mL | 0.6731 mL | 1.6828 mL | |
| 50 mM | 0.0538 mL | 0.2692 mL | 0.5385 mL | 1.3462 mL | |
| 60 mM | 0.0449 mL | 0.2244 mL | 0.4487 mL | 1.1219 mL | |
| 80 mM | 0.0337 mL | 0.1683 mL | 0.3366 mL | 0.8414 mL | |
| 100 mM | 0.0269 mL | 0.1346 mL | 0.2692 mL | 0.6731 mL |
JS6 Related Classifications
HY-152177 Related Classifications
Powered by Bioz